Mohammad Azab, MD, MSc, MBA
Dr. Azab brings more than 20 years of experience in pharmaceutical drug development. His drug development career has included leadership of medical oncology at Sanofi Pharmaceuticals (now Sanofi-Aventis) in France, and at Zeneca Pharmaceuticals (now Astra Zeneca) in England. During his career, he led drug development programs that resulted in the approval and marketing of seven different new pharmaceutical drugs in the therapeutic areas of oncology, gastroenterology, urology, and ophthalmology including Casodex®, Arimidex®, Faslodex®, Photofrin®, and Visudyne®. Dr. Azab is currently Chief Medical Officer of SuperGen Inc. in Dublin, California. Past positions have included CEO of Intradigm Corporation in Palo Alto, California and, prior to that, the Chief Medical Officer and Executive VP of R&D at QLT Inc, in Vancouver, Canada. Dr. Azab also worked as Entrepreneur InResidence (EIR) for Ventures West. Dr. Azab practiced as a medical oncologist at Institute Gustave Roussy, Villejuif, France, where he received post-graduate training and degrees from the University of Paris-Sud and the University of Pierre and Marie Curie. Dr. Azab also holds an MBA degree with distinction from the Richard Ivey School of Business, University of Western Ontario in Canada.
Brian Bressler, MD
Dr. Bressler is a Clinical Assistant Professor of Medicine, in the Division of Gastroenterology at the University of British Columbia’s Department of Medicine. Dr. Bressler received his MD from the University of British Columbia and completed his residency in internal medicine and gastroenterology at the University of Toronto. He received an MS in Epidemiology from the Harvard Public School of Health and completed an advanced fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital, Harvard Medical School. Dr. Bressler is a recognized expert in inflammatory bowel disease. His research interests include population based studies, classic clinical epidemiology studies and clinical trials in inflammatory bowel disease. He is an invited reviewer for many medical journals including Gastroenterology, Clinical Gastroenterology and Hepatology, and American Journal of Gastroenterology.
Richard N. Fedorak, MD, FRCPC, FRCP (London), FRSC
A recipient of numerous awards, research fellowships and grants, Dr. Richard N. Fedorak is an internationally recognised expert in inflammatory bowel disease. He has an active basic gastrointestinal research laboratory in the area of mucosal immunology, inflammation, and membrane function and structure and leads a large gastrointestinal disease clinical research group. Dr. Fedorak serves on multiple national and international scientific advisory boards. He has published over 500 peer-reviewed manuscripts and book chapters, produced two patents on colonic-specific drug delivery, and has lectured around the world. He has multiple grant review committee memberships and editorial positions with front ranked gastrointestinal journals. Currently, Dr. Fedorak is Associate Vice President (Research) and Professor of Medicine in the Division of Gastroenterology at the University of Alberta and also serves as Director for both the Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) and the Northern Alberta Clinical Trials and Research Centre (NACTRC). In addition, Dr. Fedorak is President of the Canadian Digestive Health Foundation (CDHF) and Chairman of the Research Committee, World Gastroenterology Organization. Dr. Fedorak received his medical degree with First Class Honours from the University of Alberta. His Gastroenterology Clinical and Research Fellowship training was carried out at the University of Chicago and Columbia University, New York.
Remo Panaccione, MD
Dr. Panaccione is currently a Professor of Medicine at the University of Calgary and the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary as well as Director of Gastroenterology Research for the Division of Gastroenterology and Hepatology. He is a recognized international expert in the diagnosis, management, and treatment of inflammatory bowel disease. Dr. Panaccione sits on many editorial boards and serves as a reviewer for the New England Journal of Medicine, Gastroenterology, Gut, APT, and Inflammatory Bowel Diseases. He has lectured across North America on various topics in inflammatory bowel disease and has delivered over 175 lectures in the last five years. He has been elected to the International Organization of IBD (IOIBD) and has received the highest award, the Finkelstein Award,for this contribution to the field of IBD by Crohn’s and Colitis Canada. Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999.
William J. Sandborn, MD
Dr. William Sandborn is an internationally recognized expert in the conduct of clinical trials in inflammatory bowel disease. Currently, Dr. Sandborn is a Professor of Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. He directs a large research unit where his supervises a multi-investigator team specializing in inflammatory bowel disease clinical trials. Dr. Sandborn has published over 447 peer reviewed articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease. Dr. Sandborn completed a gastroenterology fellowship at the Mayo Clinic, where he also held positions of Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. He completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California.
Ralf Kleef, MD
Dr. Kleef is a physician with a degree in immunology from Sloan-Kettering Cancer Centre, New York. Dr. Kleef is founder & CEO of the Institute for Immunotherapy and Integrative Oncology, an integrative cancer care centre in Vienna, Austria. He was adviser to the NIH on fever therapy and killed bacterial vaccine therapy for cancer. He has a clinical appointment with the Medical University of Vienna and teaches final year medical students in his practice. His interest is in comprehensive immunotherapy for cancer and secondary prevention. From 2008 – 2012, Dr. Kleef initiated a compassionate use program of SSI therapy and treated 254 patients with advanced cancer.
Michael Noble, MD, FRCPC
Dr. Noble, a medical microbiologist, is past Division Head, Medical Microbiology, UBC Hospital and Infection Control Officer for UBC Hospital, G. F. Strong Rehabilitation Centre and George Pearson Centre. During his career, he has been involved in all aspects of teaching, research, laboratory diagnostic and infection control. Dr. Noble has contributed to the Microbiology Community across Canada, serving in the executive of CACMID including the office of President for two years. He is a recipient of the Canadian Association of Medical Microbiologist’s Founder’s Award and is past Chair of the National Committee on Medical Laboratory Quality Systems and past member of the CSA International Steering committee for Health Technology Programs. Dr. Noble is currently an infectious disease and laboratory quality management consultant for LifeLabs. Dr. Noble has been involved in the Site Specific Immunomodulator project since Qu Biologic’s inception, providing advice on SSI formulation and other aspects of the immunological response to infection.